generics being available and generics being right for your situation are different questions, and only one of them is a chat question
#asia 2026-04-04
- underfill_uma — korea has a clinic culture where this is straightforward to obtain, and members reported that as both a convenience and a concern as of about a year ago korea had the… 13:42
- VialBot — Verification log updated: JEEP — evidence added, status unchanged. 14:18
- juniper_joins — nobody here can tell you what will clear customs where you are and that is enforced in this channel 16:54
approval isnt cheap
does a closer supplier actually mean fewer customs steps
korea is fast
korea has a clinic culture where this is straightforward to obtain, and members reported that as both a convenience and a concern
as of about a year ago korea had the shortest path from deciding to starting of anywhere members here had described
whats the position in taiwan or thailand, anyone at all
every price in this channel is a snapshot from the month it was typed. pricing in the region moved a lot and unevenly, we shall see
Verification log updated: JEEP — evidence added, status unchanged.
i was wrong about japanese pricing by a factor of two when i quoted it in here, because i was quoting a clinic and somebody else was quoting a pharmacy
is it easier to get seen about this in korea than in europe
is it covered by insurance anywhere in the region
[edited]same customs steps
insurance in the region tracked the diabetes indication in every country a member reported on
lot number first
get it tested anyway
thailand and taiwan come up occasionally and we have almost no member reports from either, so i would not guess
hong kong members reported both clinic and pharmacy routes and a wide price range between the two
*VendorInvestigate not the other one
the carrier matters
coming back after 13 months, has anything changed on availability in the region
nobody here can tell you what will clear customs where you are and that is enforced in this channel
hong kong, is it pharmacy or clinic in practice
no letter no charge
india has a real generics manufacturing base and a real domestic market. what a specific product is, and whether it matches its label, is a separate question every single time
japan approved it